Trichomegaly and poliosis of the eyelashes during cetuximab treatment of metastatic colorectal cancer

Journal of Clinical Oncology

Volumn 29, Issue 18, 2011, Pages

  Rodriguez, Nelson A ^a   Ascaso, Francisco J ^b  

^a Universidad Pública de Navarra   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CASE REPORT; COLORECTAL CANCER; DISEASE ASSOCIATION; DRUG WITHDRAWAL; EYELASH; EYELID DISEASE; FEMALE; HAIR DISEASE; HUMAN; LIVER CANCER; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PHYSICAL EXAMINATION; POLIOSIS; PRIORITY JOURNAL; RECURRENT CANCER; TREATMENT DURATION; TRICHOMEGALY; TUMOR GROWTH;

ADENOCARCINOMA; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; EYELASHES; FEMALE; FLUOROURACIL; HAIR COLOR; HEPATECTOMY; HUMANS; HYPERTRICHOSIS; LEUCOVORIN; LIVER NEOPLASMS; NEOPLASM PROTEINS; ORGANOPLATINUM COMPOUNDS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 79959319063     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.34.6858     Document Type: Article

References (25)

1. Agero AL, Dusza SW, Benvenuto-Andrade C, et al: Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 55:657-670, 2006 (Pubitemid 44436627)
2. Bonner JA, Harari PM, Giralt J, et al: Radiotherapy plus cetuximab for squamous cell carcinoma of the head and neck. N Engl J Med 354:567-578, 2006 (Pubitemid 43209104)
3. Montagut C, Grau JJ, Grimalt R, et al: Abnormal hair growth in a patient with head and neck cancer treated with the anti-epidermal growth factor receptor monoclonal antibody cetuximab. J Clin Oncol 23:5273-5275, 2005 (Pubitemid 46224050)
4. Braiteh F, Kurzrock R, Johnson FM: Trichomegaly of the eyelashes after lung cancer treatment with the epidermal growth factor receptor inhibitor erlotinib. J Clin Oncol 26:3460-3462, 2008
5. Vano-Galvan S, de las Heras E, Harto A, et al: Severe cutaneous toxicity during concomitant radiotherapy and cetuximab treatment of head and neck cancer. Eur J Dermatol 18:471-472, 2008 (Pubitemid 352031870)
6. Kerob D, Dupuy A, Reygagne P, et al: Facial hypertrichosis induced by Cetuximab, an anti-EGFR monoclonal antibody. Arch Dermatol 142:1656-1657, 2006 (Pubitemid 44969235)
7. Vano-Galvan S, Moreno-Martin P, Jaén P: Progressive trichomegaly. Neth J Med 67:35-36, 2009
8. Bambury R, McCaffrey JA: Trichomegaly of the eyelashes after colorectal cancer treatment with the epidermal growth factor receptor inhibitor cetuximab. Clin Colorectal Cancer 8:235, 2009
9. Bouché O, Brixi-Benmansour H, Bertin A, et al: Trichomegaly of the eyelashes following treatment with cetuximab. Ann Oncol 16:1711-1712, 2005 (Pubitemid 41510151)
10. Vaccaro M, Pollicino A, Barbuzza O, et al: Trichomegaly of the eyelashes following treatment with cetuximab. Clin Exp Dermatol 34:402-403, 2009
11. Foerster CG, Cursiefen C, Kruse FE: Persisting corneal erosion under cetuximab (Erbitux) treatment (epidermal growth factor receptor antibody). Cornea 27:612-614, 2008
12. Melichar B, Nemcová I: Eye complications of cetuximab therapy. Eur J Cancer Care (Engl) 16:439-443, 2007
13. Dueland S, Sauer T, Lund-Johansen F, et al: Epidermal growth factor receptor inhibition induces trichomegaly. Acta Oncol 42:345-346, 2003 (Pubitemid 36851154)
14. Roe E, Garcia MP, Marcuello E, et al: Description and management of cutaneous side effects during cetuximab or erlotinib treatments: A prospective study of 30 patients. J Am Acad Dermatol 55:429-437, 2006 (Pubitemid 44189595)
15. Vano-Galvan S, Ríos-Buceta L, Ma DL, et al: Cetuximab-induced hypertrichosis of the scalp and eyelashes. J Am Acad Dermatol 62:531-533, 2010
16. Bagazgoitia L, Aboín S, Beà S, et al: Trichomegaly due to cetuximab. Med Clin (Barc) 133:323, 2009
17. Cohen PR, Escudier SM, Kurzrock R: Cetuximab-associated elongation of the eyelashes: Case report and review of eyelash trichomegaly secondary to epidermal growth factor receptor inhibitors. Am J Clin Dermatol 12:63-67, 2011
18. Vergou T, Stratigos AJ, Karapanagiotou EM, et al: Facial hypertrichosis and trichomegaly developing in patients treated with the epidermal growth factor receptor inhibitor erlotinib. J Am Acad Dermatol 63:e56-58, 2010
19. Saif MW, Gnanaraj J: Erlotinib-induced trichomegaly in a male patient with pancreatic cancer. Cutan Ocul Toxicol 29:62-66, 2010
20. Márquez G, Herrera-Acosta E, Vidal I, et al: A case of trichomegaly of the eyelashes and facial hypertrichosis induced by erlotinib (Tarceva). Int J Dermatol 48:97-98, 2009
21. Shah NT, Kris MG, Pao W, et al: Practical management of patients with non - small-cell lung cancer treated with gefitinib. J Clin Oncol 23:165-174, 2005 (Pubitemid 41702635)
22. Cunningham D, Humblet Y, Siena S, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345, 2004 (Pubitemid 38944402)
23. Albanell J, Rajo F, Averbuch S: Pharmacodynamic studies in the epidermal growth factor receptor inhibitor ZD in skin from cancer patients: Histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 20:110-124, 2002 (Pubitemid 34032602)
24. Busam KJ, Capodieci P, Motzer R, et al: Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 144:1169-1176, 2001 (Pubitemid 34204207)
25. Sriprakash K, Godbolt A: Vitiligo-like depigmentation induced by imiquimod treatment of superficial basal cell carcinoma. Australas J Dermatol 50:211-213, 2009